SCHEMBL7149836

SCHEMBL7149836

COc1cccc(NS(=O)(=O)CCCSc2nc3ccccc3s2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
HSD17B10 Q99714 1/20 0.51
MAPT P10636 6/20 0.48
LMNA P02545 6/20 0.48
HTT P42858 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
KMT2A Q03164 1/20 0.47
CYP1A2 P05177 3/20 0.47
CYP2C19 P33261 2/20 0.47
POLB P06746 2/20 0.47
IDO1 P14902 1/20 0.47
TP53 P04637 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
CYP2D6 P10635 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GFER P55789 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7155045 0.97 ALDH1A1 (0.50) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7151736 0.94 ALDH1A1 (0.56) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7148790 0.92 MAPT (0.50) ALDH1A1MAPTLMNAHTTNPC1
SCHEMBL7147065 0.90 LMNA (0.46) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7152202 0.89 MAPT (0.49) ALDH1A1MAPTLMNAHTTNPC1
SCHEMBL7151773 0.89 ALDH1A1 (0.54) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7144781 0.88 MAPT (0.52) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7147570 0.87 ALDH1A1 (0.54) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7153984 0.87 LMNA (0.46) ALDH1A1HSD17B10MAPTLMNAHTT
SCHEMBL7149249 0.86 ALDH1A1 (0.53) ALDH1A1HSD17B10MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 ALDH1A1 2919/4885HSD17B10 2088/4885MAPT 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.